靶向分子影像学在泌尿肿瘤学中的生物标志物作用。
Targeted Molecular Imaging as a Biomarker in Urologic Oncology.
机构信息
Department of Radiology, Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit St, Wht 427, Boston, MA 02114, USA; Center for Precision Imaging, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 55 Fruit St, Wht 427, Boston, MA 02114, USA.
Department of Radiology, Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit St, Wht 427, Boston, MA 02114, USA; Center for Precision Imaging, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 55 Fruit St, Wht 427, Boston, MA 02114, USA.
出版信息
Urol Clin North Am. 2023 Feb;50(1):115-131. doi: 10.1016/j.ucl.2022.09.011.
Urologic malignancies constitute a large portion of annually diagnosed cancers. Timely diagnosis, accurate staging, and assessment of tumor heterogeneity are essential to devising the best treatment strategy for individual patients. The high sensitivity of molecular imaging allows for early and sensitive detection of lesions that were not readily detectable using conventional imaging techniques. Moreover, molecular imaging enables the interrogation of molecular processes used in targeted cancer therapies and predicts cancer response to treatment. Here we review the current advancements in molecular imaging of urologic cancers, including prostatic, vesical, renal testicular, and ureteral cancers.
泌尿系统恶性肿瘤是每年诊断出的癌症的主要组成部分。及时诊断、准确分期和评估肿瘤异质性对于为个体患者制定最佳治疗策略至关重要。分子成像的高灵敏度使得能够早期且敏感地检测到常规成像技术不易检测到的病变。此外，分子成像还可以检测靶向癌症治疗中使用的分子过程，并预测癌症对治疗的反应。在这里，我们回顾了泌尿系统癌症的分子成像的最新进展，包括前列腺癌、膀胱癌、肾癌、睾丸癌和输尿管癌。
Zotero 插件